Revenue
2019
2020
2021
2022
2023
2024
2025
aTYR PHARMA INC (ATYR)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $190,000 | $235,000 | $353,000 | $10.4M | $0 | $10.5M | $422,000 | — | — | — | — | — | — |
| Research & development | $60.2M | $54.4M | $42.3M | $42.8M | $23.3M | $17.3M | $14.0M | $20.4M | $30.1M | $42.8M | $34.5M | $16.8M | $13.8M |
| Operating expenses | $77.8M | $68.1M | $55.3M | $56.8M | $34.0M | $26.4M | $23.4M | $32.8M | $47.1M | $57.9M | $47.6M | $23.6M | $19.5M |
| Operating income | −$77.6M | −$67.9M | −$54.9M | −$46.4M | −$34.0M | −$15.9M | −$23.0M | −$32.8M | −$47.1M | −$57.9M | −$47.6M | −$23.6M | −$19.5M |
| EBITDAderived | −$77.0M | −$67.2M | −$54.3M | −$46.2M | −$33.5M | −$15.3M | −$22.3M | −$32.1M | −$46.4M | −$57.0M | −$46.7M | −$22.7M | −$18.8M |
| Net income | −$74.1M | −$64.0M | −$50.4M | −$45.3M | −$33.8M | −$16.2M | −$16.2M | −$34.5M | −$48.2M | −$57.9M | −$48.0M | −$24.4M | −$20.0M |
| Basic EPSper diluted share | -$0.80 | -$0.86 | -$0.94 | -$1.60 | -$1.77 | -$1.77 | -$7.03 | -$16.11 | -$26.13 | -$2.44 | -$3.03 | -$29.69 | -$28.39 |
| Diluted EPSper diluted share | -$0.80 | -$0.86 | -$0.94 | -$1.60 | -$1.77 | -$1.77 | -$7.03 | -$16.11 | -$26.13 | -$2.44 | -$3.03 | -$29.69 | -$28.39 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 27, 2026Form 4 | SCHIMMEL PAULDirector | BuyCommon Stock · indirect | 100.0K | $0.50 | $50.0K | 779.1K |
| Feb 4, 2026Form 4 | Shukla SanjayPresident and CEO | SellCommon Stock | 3.7K | $0.98 | $3.7K | 153.6K |
| Feb 4, 2026Form 4 | Broadfoot Jill MarieChief Financial Officer | SellCommon Stock | 1.6K | $0.98 | $1.5K | 37.3K |
| Feb 4, 2026Form 4 | DENYES NANCYGeneral Counsel | SellCommon Stock | 1.1K | $0.98 | $1.1K | 33.1K |
| Oct 9, 2025Form 4 | SCHIMMEL PAULDirector | BuyCommon Stock · indirect | 318.0K | $0.94 | $298.9K | 1.41M |